Unlock personalized cancer care. Book a Test Now
This is to bring to your notice that SOT Therapy from RGCC is not available in Singapore
Unlock personalized cancer care. Book a Test Now
This is to bring to your notice that SOT Therapy from RGCC is not available in Singapore
Onco-D-Clare
Onco-D-Clare test takes a proactive step towards early cancer detection and your informed well-being. This test is uniquely tailored for people without symptoms but with a desire for early intervention.
With the ease of a simple blood draw, you can now detect cancer long before any symptoms emerge. Onco-D-Clare opens an early door to personalized health insights.
Onco-D-Clare analyzes the details of your gene expressions by combining gene expression analysis and machine learning algorithms.
The Onco-D-Clare test goes beyond traditional screening, aiming to detect cancer at its earliest stages. This revolutionary screening test goes beyond established norms, comprehensively analyzing your cancer risk even before your body shows any signs.
Peripheral Blood Mononuclear Cells (PBMCs) are key players in your immune system, including T cells, B cells, NK cells, and monocytes.
These cells are responsible for identifying and responding to abnormal cells in your body, including cancer cells.
By analyzing the gene expression of these PBMCs, we can detect the earliest signs of cancer before it even becomes visible in other tests.
Reserve your 15-minute free one on one discussion
Our test is clinically validated and boasts an impressive accuracy rate of approximately 93%. This level of reliability instills confidence in your results, enabling you to make informed decisions.
By analyzing over 90 genes as part of the Onco-D-Clare test, we generate a comprehensive gene expression profile.
With Onco-D-Clare, you gain the opportunity for timely intervention and improved outcomes.
Oncotrail has undergone rigorous evaluation to ensure high sensitivity and specificity, making it an invaluable tool for diagnostic purposes.
Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This would objectively provide information on how well the treatment is going.
The non-invasive tracking of the cancer status would notify a treating physician whether to adjust current management or stay the course. This would be important to know in almost real-time rather than to find out much later that a treatment doesn't apply to a particular person.
Whole peripheral blood sample
5-8 ml peripheral whole blood
Approx. 7 business days
21 business days after sample collection
All types of cancer except brain and CNS (central nervous system) cancers
To whom it is relevant: The test is recommended for those who have a family history of cancer, individuals who are exposed to occupational hazards, and individuals who wish for a cancer screening.
A patient-centric revolution in cancer testing and monitoring. We are devoted to providing personalized tests designed with each patient’s unique genetic profile in mind.
RGCC Global Ltd
Suite 1701-02, 17/F, FWD Financial Centre, 308 Des Voeux Road Central, Hong Kong
202312501N
+852 7028 5202
IAS Accreditation Testing Laboratory
ISO 22000: 2018
Nr.: 20101200002689
ISO 22716: 2007
Nr.: 20019220006394
College of American Pathologists
Certificate of Accreditation
CAP#: 9239089
CLIA#: 99D2283882
Accreditation Certificate of Foreign Cell Processor
– Japanese Government
IAS Accreditation Medical Laboratory
ISO 45001: 2018
Nr.: 20152220006395
CLIA ID Number 99D2283882
Certificate of GMP Compliance
No. 512863-102689104
Production License for Investigational ATMPs for Human Use
Ref. No. 7282
©2025 Copy Right
